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Purpose: To determine the reproducibility of TWIST-
derived (Time-Resolved Angiography with Interleaved Sto-
chastic Trajectories) quantitative dynamic contrast
enhanced (DCE) MRI in a uterine fibroid model.
Materials and Methods: The institutional review board
approved this retrospective study. Dynamic contrast-
enhanced TWIST datasets from 15 randomly selected 1.5
Tesla pelvic MR studies were postprocessed. Five readers
recorded kinetic parameters (Ktrans [volume transfer con-
stant], ve [extracellular extravascular space volume], kep
[flux rate constant], iAUC [initial area under the gadolin-
ium-time curve]) of the largest uterine fibroid using three
region-of-interest (ROI) selection methods. Measurements
were randomized and repeated three times, and measures
of reproducibility were calculated.
Results: The intra-rater coefficients of variation (CVs,
brackets indicate 95% confidence intervals) varied from
4.6% to 7.6% (Ktrans 7.6% [6.1%, 9.1%], kep 7.2% [5.9%,
8.5%], ve 4.6% [3.8%, 5.4%], and iAUC 7.2% [6.1%,
8.3%]). ve was the most reproducible (P < 0.05). Inter-
rater reproducibility was significantly (P < 0.05) greater
for the large ROI method (range of intraclass correlation
coefficients [ICCs] ¼ 0.80–0.98 versus 0.48–0.63 [user-
defined ROI] versus 0.41–0.69 [targeted ROI]). The uterine
fibroid accounted for the greatest fraction of variance for
the large ROI method (range across kinetic parameters:
83–98% versus 56–69% [user-defined ROI] versus 47–
74% [targeted ROI]). The reader accounted for the greatest
fraction of variance for the user-defined ROI method (0.4–
14.1% versus 0.1–3.0% [large ROI] versus <0.1–1.5%
[targeted ROI]).
Conclusion: Changes in TWIST-derived DCE-MRI kinetic
parameters of up to 9–15% may be attributable to mea-
surement error. Large DCE-MRI regions of interest are the
most reproducible across multiple readers.
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NONINVASIVE BIOMARKERS THAT can be used to
monitor drug efficacy or disease status have gained
increasing attention in the scientific and medical
communities. MRI is an attractive imaging modality
because it provides a combination of qualitative and
quantitative information. The ability to predict bio-
logic behavior with minimal side effects is enticing,
but this first requires validation to show that it is
reproducible and that the biologic effect size is greater
than the error inherent in the measurement.
Quantitative dynamic contrast-enhanced MRI (DCE-
MRI) is a method of indirectly measuring the perfu-
sion characteristics of a given tissue by acquiring
repeated T1-weighted images following the intrave-
nous administration of a gadolinium-based contrast
material. Several commercial and public postprocess-
ing tools are available that allow one to characterize
the results of this data acquisition in the form of mul-
tiple kinetic parameters using a two-compartment
Tofts paradigm (1): Ktrans (volume transfer constant
between plasma and extracellular extravascular space
[EES]), ve (EES volume), and kep (flux rate constant
between EES and plasma). The iAUC (initial area
under the gadolinium curve at 60–90 s) has also been
considered a meaningful indicator of tissue perfusion
(2–4). Many authors have suggested that use of these
parameters may allow longitudinal monitoring of
tumor biology (2–9).
However, DCE-MRI has considerable potential for
systematic error. There are numerous factors that can
affect the quantitative output. Therefore, data
obtained at different sites or times may be difficult if
not impossible to compare. We sought to assess the
reproducibility of DCE-MRI kinetic parameter
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measurements when they are performed under con-
trolled conditions, with as many sources of variation
removed as possible (e.g., inputting the same DCE
dataset into the same postprocessing workstation and
calculating kinetic parameters using the same post-
processing algorithm and an identical arterial input
function). We wanted to test the null hypothesis that
under tightly controlled conditions there would be
minimal variation within and between DCE-MRI read-
ers. The purpose of our study was to determine the
reproducibility of TWIST-derived quantitative DCE-
MRI in a uterine fibroid model.
MATERIALS AND METHODS
Before the initiation of this investigation, Institutional
Review Board approval was obtained. The study was
carried out in compliance with the Health Insurance
Portability and Accountability Act (HIPAA, USA).
Patient informed consent was not required based on
institutional policy and the retrospective nature of
this investigation.
Subjects
All (N ¼ 34) 1.5 Tesla (T) DCE pelvic MR studies per-
formed before possible uterine fibroid embolization
from August 21, 2009, to December 17, 2010, were
identified by a retrospective review of the institutional
electronic medical record system. None of the patients
had previously undergone uterine artery embolization.
A power calculation was performed prospectively to
determine sample size adequacy. Effect size and
standard deviation were estimated using nonpub-
lished institutional pilot data (a significance level of
0.05 and statistical power of 0.8 were used for all
calculations). The following assumptions were used:
Ktrans (standard deviation [SD] 0.3, effect size 0.3,
needed sample size ¼ 10), ve (SD 0.2, effect size 0.3,
needed sample size ¼ 6), iAUC (SD 15, effect size 15,
needed sample size ¼ 10). Based on these calcula-
tions and assumptions, a conservative sample size of
15 was selected.
Of the 34 1.5T DCE pelvic MR studies retrieved in
our initial query, four studies were excluded because
they were performed on a unique MR system, one was
excluded for erroneous capture (it was actually a
pelvic MR venogram), one was excluded because it
lacked a variable flip angle T1 map, and one was
excluded because the largest uterine fibroid was too
small to adequately measure (<1 cm in size). This left
a total of 27 appropriate DCE pelvic MR studies with
variable flip angle T1 maps performed on identical
1.5T systems (Siemens Avanto, Erlangen, Germany)
and enhanced with 0.1 mmol/kg gadobenate dimeglu-
mine (Bracco Diagnostics, Princeton, NJ) injected
intravenously at 2 mL/s followed by a 20-mL saline
flush at 2 mL/s. The mean volume of administered
intravenous contrast material was 14.9 mL (range,
10–20 mL). Fifteen of these 27 studies were randomly
selected based on the power calculation using a pseu-
dorandom number generator in Microsoft Excel
(Microsoft, Redmond, WA). These 15 studies com-
prised the study group.
Imaging Protocol
All DCE pelvic MR imaging studies were performed on
the same 1.5T system (Siemens Avanto, Erlangen,
Germany) in supine position with two anterior 6-ele-
ment body phased-array coils and two 3-element
posterior spine array coils. Background tissue T1
relaxation times were measured using a previously
described variable flip angle technique with a three-
dimensional (3D) spoiled gradient recalled echo
sequence at 2, 8, and 20 degrees, respectively (10).
Scanning parameters were as follows: echo time (TE)
1.31 milliseconds (ms); repetition time (TR) 3.74 ms;
matrix 256  205; FOV 400  400 millimeter (mm);
slice thickness 3–4 mm; phase encoding steps 153;
echo train length 1; number of excitations (NEX) 4;
parallel imaging acceleration factor 2. Dynamic con-
trast enhancement was imaged using a 4D, time
resolved MR angiography sequence with interleaved
stochastic trajectories (TWIST). A total of 30 consecu-
tive measurements with a mean temporal resolution
of 6.2 s (range, 5.3–9.0 s) resulted in a mean temporal
coverage of 3.1 min (range, 2.7–4.5 min). Except for
NEX 1, flip angle 12 and phase encoding steps 163;
all other sequence parameters were matched exactly
to the T1 map. T1 mapping and DCE imaging were
performed in the coronal orientation to minimize
motion artifact. The number of slices acquired per
sequence was individually adjusted between subjects
to the volume of interest and ranged from 48–80.
Within each subject, the number of slices per tempo-
ral series was constant.
Perfusion Data Postprocessing
All DCE MRI studies were postprocessed (Tissue 4D,
Siemens Healthcare) to obtain the quantitative
perfusion parameters described above. The software
calculated a voxel-wise Levenberg Marquardt fit to a
two-compartment Tofts model (11), as well as the
iAUC. Those voxel-wise parameters were then aver-
aged over the selected ROI to obtain the quantitative
parameters for the ROI.
A region of interest was placed in either the left
common iliac artery or left external iliac artery on a
representative coronal image to acquire a manual AIF.
The artery with the least motion artifact was selected.
An ROI was recorded for each dataset before quantita-
tive analysis. The signal intensity over time curve was
plotted to determine the contrast arrival time for each
case. The contrast arrival time was determined by the
postprocessing software, which analyzed the shape of
the time signal intensity curve generated by the region
of interest drawn in the inflow vessel (12). This gener-
ated a mean contrast arrival time of 0.33 min (range,
0.24–0.43 min). The contrast arrival time was refer-
enced by the postprocessing workstation to access a
library of population-averaged bi-exponential AIFs. An
intermediate model AIF was selected for analysis in
all cases from among the options of: fast, intermediate
330 Davenport et al.
and slow. The contrast arrival times for each of the
datasets were recorded on the readers’ data collection
worksheet. This allowed each of the five readers to
use the same AIF model.
Regions of Interest
Three two-dimensional region-of-interest (ROI) selec-
tion methods were chosen to test the variability in
different types of measurements that might be per-
formed in clinical practice. These regions of interest
were directed toward the largest uterine fibroid in
each case, which was preidentified for the readers by
slice position and a written anatomic description (see
Data Worksheet and Data Collection, below). These
ROIs included: (i) a user-defined ROI with instruc-
tions to assess ‘‘the most enhancing component’’ of
the target uterine fibroid (using a combination of early
time point and kinetic parametric mapping image
review), (ii) a large ROI encompassing at least three-
quarters of the target uterine fibroid on the largest
coronal section, and (iii) a targeted ROI of user-deter-
mined size directed to the target uterine fibroid at a
specific location and slice position (Fig. 1). A specific
size for the user-defined and targeted ROIs was not
prescribed. The readers were instructed that the ROIs
should not extend outside the margins of the target
uterine fibroid and they were cautioned to avoid par-
tial volume effects.
Data Worksheet and Data Collection
A data collection worksheet was created for each
reader that targeted in advance the largest uterine
fibroid in each patient. The location of each fibroid
was specified using a representative slice location and
series number, as well as a written anatomic descrip-
tion. For each patient, the following data were also
specified: (i) the dose of intravenous contrast material
administered (0.1 mmol/kg; range: 10–20 mL), (ii) the
type of contrast material (gadobenate dimeglumine,
Bracco Diagnostics, Princeton, NJ), and (iii) the AIF
contrast arrival time.
Each combination of ROI method, uterine fibroid,
and kinetic value (Ktrans, kep, ve, and iAUC) was meas-
ured and recorded three separate times by each of the
five (MSD, TH, JJH, SRB, SF) readers (i.e., 36 values
per fibroid per reader). The order of ROI placement
was randomized on the data collection worksheet
using a pseudorandom number generator in Microsoft
Excel (Microsoft, Redmond, WA). Each set of three
unique ROI selection methods (large ROI, user-
defined ROI, and targeted ROI) was completed before
the subsequent set was begun. After each set of
unique ROI selection methods was completed, all
ROIs were deleted from the images before the next set
of was begun.
Before initiating data analysis, all readers were fam-
iliarized with the postprocessing workstation, trained
to identify the target lesions by the methods described
above, and practiced using postperfusion processing
on nonstudy cases using the same instructions as
they used for the study group. All readers were eval-
uated before study initiation by an experienced reader
in MR perfusion analysis (blinded for review) to
ensure competency with the task. All readers were
familiar with the appearance of uterine fibroids and
knew how to identify the target uterine fibroid using
the localization information on the worksheet.
Data Analysis
Intra-rater reproducibility was assessed by calculating
the coefficient of variation (CV ¼ standard deviation
[SD] / mean) for each set of three repeated ROI meas-
urements. The estimated measurement error was
determined by multiplying the mean CVs by 1.96. To
determine if the CVs were influenced by any of the
tested variables (reader, uterine fibroid, ROI method),
a stepwise analysis of variance (ANOVA) was per-
formed for all main effects using the minimum Bayes
information criterion to select the best model.
Inter-rater agreement was directly assessed by cal-
culating intraclass correlation coefficients (ICC)
between readers for each ROI method and kinetic pa-
rameter. Inter-rater agreement was also assessed
using a random-effect ANOVA to determine if any of
the tested effects had an effect on the mean perfusion
values measured and to determine the proportion of
variance explained by each effect. In all cases, the
modeled effects included: ROI method, reader, and
individual uterine fibroid. The readers and uterine fib-
roids were considered random effects, and the ROI
method was considered a fixed effect.
One Ktrans data point and three kep data points out
of 2700 total data points were excluded from analysis
because they were extreme outliers (8–11 SD away
from the mean) and believed to most likely represent
transposition errors.
Fibroid volume was calculated using the following
formula:
½length  width  height  0:52:
All statistical analysis was performed (BD) using
JMP v 9.0 (SAS, Cary, NC). Numbers in brackets indi-
cate 95% confidence intervals.
RESULTS
There were 15 uterine fibroids in 15 female patients
with a mean age of 44 years (range, 28–60 years), a
mean height of 1.65 meters (range, 1.52–1.83 m), and
a mean weight of 75.8 kg (range, 54.4–136.5 kg). The
mean uterine fibroid volume was 211 cm3 (range,
1.49–637 cm3). The mean maximum uterine fibroid
diameter was 7.6 cm (range, 1.7–11.9 cm). Two uter-
ine fibroids were located within the lower uterine seg-
ment, four were in the uterine body, and nine were in
the uterine fundus. Four uterine fibroids were charac-
terized as subserosal and 11 were characterized as
intramural. One fibroid was extensively necrotic, with
greater than 75% nonenhancing volume; five fibroids
were moderately necrotic, with approximately 25–75%
nonenhancing volume; one fibroid was mildly
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Figure 1. a–c: Representative T1-weighted dynamic contrast-enhanced subtraction images and nonsubtracted parametric
maps (Ktrans is mapped in these examples) for each of the three region-of-interest (ROI) types used during data collection: (a)
large ROI, (b) user-directed ROI, and (c) targeted ROI.
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necrotic, with less than 25% nonenhancing volume;
and eight fibroids showed no measurable necrosis.
The mean CVs and 95% confidence intervals for
intra-rater kinetic parameter reproducibility were:
Ktrans 7.6% [6.1%, 9.1%], kep 7.2% [5.9%, 8.5%], ve
4.6% [3.8%, 5.4%], and iAUC 7.2% [6.1%, 8.3%].
Based on these mean CVs, the quantitative DCE mea-
surement error is estimated at 9–15%. The iAUC CV
was significantly (P ¼ 0.0002) influenced by the
reader, but accounted for a relatively small fraction of
the total variance with an adjusted R2 of 0.08. The
Ktrans and kep CVs were not strongly influenced by
any of the tested factors according to the Bayes mini-
mum information criterion. The individual intra-rater
CVs for each combination of ROI selection method
and kinetic parameter are displayed in Table 1.
Inter-rater reproducibility of all kinetic parameters as
expressed by ICCs was significantly (P < 0.0001) greater
for the large ROI method (ICCs ¼ 0.80–0.98) compared
with the user-defined (ICCs ¼ 0.48–0.63) and targeted
(ICCs ¼ 0.41–0.69) ROI methods. Table 2 lists the
ICCs for each kinetic parameter and ROI selection
method. The large ROI method had the highest agree-
ment between readers, indicating that encompassing a
large fraction of the mass/uterine fibroid in the ROI has
the highest inter-rater reproducibility. Although the
user-defined ROI had the greatest intra-rater agree-
ment, it had the lowest inter-rater agreement.
Table 3 lists the fraction of variance explained for
each kinetic parameter by uterine fibroid, reader, and
random error. The fraction of variance explained by
differences in the measured uterine fibroid (as
opposed to the reader or unexplained error) was great-
est using the large ROI method (83–98%) compared
with the user-defined (56–69%) and targeted (47–74%)
ROI methods. The reader contributed the greatest
fraction of variance when the user-defined ROI was
used (0.4–14.1% versus 0.1–3.0% [large ROI] versus
<0.1–1.5% [targeted ROI]).
The large ROI method had significantly lower (P <
0.0001) iAUC values (17.2 mmol/s [16.5, 17.8]) com-
pared with the targeted (22.6 mmol/s [22.0, 23.3])
and user-defined ROIs (24.7 mmol/s [24.0, 25.3]),
Ktrans values (P < 0.0001, 0.32/min [0.31, 0.34], tar-
geted ¼ 0.45/min [0.44, 0.47], user-defined ¼ 0.52/
min [0.50, 0.53]), and ve values (P < 0.0001, 0.54 mL
[0.53,0.55], targeted ¼ 0.59 mL [0.58,0.61], user-
defined ¼ 0.62 mL [0.61,0.63]). The kep values were
not significantly different (P ¼ 0.86) for the different
ROI methods (0.95 [0.91,1.00]).
DISCUSSION
Noninvasive imaging-based in vivo monitoring of tu-
mor biology and drug efficacy offers the potential to
change the medical paradigm by individualizing onco-
logic therapy. However, before such an approach can
be used in a widespread manner, it is important that
a thorough analysis be first performed on the imaging
modality itself to quantify the inherent systematic
error. If an imaging biomarker suffers from a lack of
reproducibility—within readers, between readers, or
between sites—then results gleaned from these imag-
ing studies will be difficult to interpret and, therefore,
difficult to place in a clinical context.
DCE-MRI is one such biomarker that holds great
promise but suffers from several confounding factors.
Results obtained at one time point may be rendered
incomparable to those obtained at a different time
point if even one among a whole variety of factors
have been changed in the interval (e.g., TR, flip angle,
radiofrequency transmit field (B1), 2D versus 3D
sequence type, temporal resolution, contrast material
dose and injection rate, saline flush dose and injec-
tion rate, patient body size, patient body position,
patient motion, proximity of the organ of interest to
the magnet isocenter, matrix size, field strength, mag-
net manufacturer, postprocessing algorithm, arterial
Table 1
Intra-rater Reproducibility Expressed as the Coefficient of Variation (CV) for Each Kinetic Parameter and Region of Interest (ROI)
Selection Method*
Intra-rater CVs
Large ROI Targeted ROI User-defined ROI
iAUC 7.0% [4.6%, 9.4%] 6.9% [5.3%, 8.4%] 7.6% [5.9%, 9.3%]
Ktrans 5.7% [4.3%, 7.0%] 8.9% [5.2%, 12.5%] 8.3% [6.0%, 10.5%]
Kep 5.0% [3.5%, 6.5%] 6.5% [4.8%, 8.3%] 10.2% [7.1%, 13.3%]
ve 3.9% [2.8%, 5.1%] 4.2% [3.1%, 5.3%] 5.6% [3.6%, 7.5%]
*The brackets indicate 95% confidence intervals.
Table 2
Inter-rater reproducibility expressed as the intraclass correlation coefficient (ICC) between raters for each combination of ROI selection
method and kinetic parameter*
Inter-rater ICCs
Large ROI Targeted ROI User-defined ROI
iAUC 0.80 [0.78, 0.82] 0.68 [0.64, 0.71] 0.63 [0.59, 0.67]
Ktrans 0.88 [0.86, 0.89] 0.69 [0.65, 0.72] 0.62 [0.58, 0.66]
Kep 0.98 [0.98, 0.99] 0.41 [0.36, 0.47] 0.48 [0.43, 0.53]
ve 0.87 [0.85, 0.88] 0.66 [0.63, 0.70] 0.58 [0.54, 0.63]
*The brackets indicate 95% confidence intervals.
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input function (AIF), presence or absence of back-
ground T1 correction, region of interest (ROI) size,
ROI placement, etc.). This becomes particularly chal-
lenging for multi-site studies. However, even if all
study parameters are maintained, there is still the
considerable possibility for intra- and inter-observer
variation, as well as errors or variance in the postpro-
cessing method. Our study is an attempt to quantify
this variation in a rigorous manner for TWIST-derived
DCE datasets using identical source data and post-
processing methods.
There exists previous work that has assessed DCE-
MRI reproducibility. Padhani et al in 2001 (13)
directly measured the intra-observer reproducibility of
Ktrans and ve in normal tissue (muscle and bone) for
patients with prostate cancer who were undergoing
androgen deprivation therapy. They used single-sec-
tion spoiled gradient echo fast low angle shot (FLASH)
or five-section saturation recovery turbo-FLASH
sequences to acquire DCE T1-weighted datasets with
a temporal resolution of 9–10 s over 6.3–7.0 min. Two
datasets using identical protocols were obtained
within a mean time of 119 days. They found that the
within-subject Ktrans values had such substantial var-
iation that it precluded CV calculations (mean Ktrans:
0.126–0.554/min, SD: 0.189–0.331/min), while the
ve values had a within-subject CV of 19–26%. A simi-
lar study (14) using paired (obtained within one week)
T1-weighted spoiled gradient echo FLASH datasets
found similar magnitude within-subject CVs for a
diverse set of malignant masses (Ktrans 29%, kep 24%,
ve 9%, iAUC 12%), and greater magnitude within-sub-
ject CVs for benign muscle (kep 49%, ve 16%, iAUC
17%). The within-subject Ktrans CV for normal muscle
could not be calculated. For the malignant masses in
this study, the authors predicted that Ktrans would
need to decrease by 45% or increase by 83% within
an individual to be confident that the change was not
due to error or background fluctuation.
Other studies have reported within-subject variation
for a variety of tissue types ranging from 8.9% to 24%
for the quantitative kinetic parameters assessed in
this study (15–20). These studies have also in general
relied upon measurement comparisons obtained at
two separate time points in the same patient without
intervening therapy. Therefore, those measures of
within-subject variation include any biologic variation
that might occur from day-to-day in a given patient,
variation induced by differences in patient position-
ing, as well as variation that might occur within or
between MR systems. Our study eliminated that vari-
ation by simply assessing the within-subject variation
in an identical DCE dataset, making measurements at
multiple times in different ways within and between
readers. Thus, our within-subject CVs (4.6–7.6%)
were lower than published data, representing a lower-
bound on variability given controlled circumstances.
We would expect that if data were obtained using this
technique in the same patients on different days, with
more ill-defined masses, our CVs would be even
greater (i.e., measurement error þ biologic error).
In either case, our data strongly suggest that reader
variation (within and between), ROI selection method,
and possibly postprocessing variation (despite identi-
cal input parameters) are noteworthy impediments to
quantitative DCE-MRI reproducibility. Although seem-
ingly little can be done to improve intra- and inter-
rater variation (other than adequate training), consis-
tency in ROI selection method is important. In clinical
practice, it may be difficult to replicate a perfusion
measurement during longitudinal follow-up if specific
details regarding the ROI selection method are not
included in the Radiology report. Our data demon-
strate that the user-directed ROI had the least inter-
rater reproducibility. When readers were given the
freedom to place the ROI where they believed most
appropriate, the variation increased. In our study, the
large ROI had the best inter-rater reproducibility.
Larger ROIs can average differences in perfusion
within a heterogeneous mass and are better able to
accommodate differences between readers.
We intentionally selected uterine fibroids for our
model because they were easy for readers to identify,
circumscribed, and represented a range of perfused
tissue (from centrally necrotic to homogeneously
enhancing to nonenhancing). All of the uterine fib-
roids in this study were sharply demarcated and
greater than 1.5 cm in diameter. We believed these
features would reduce error introduced by difficulty
with lesion identification and thereby reduce the influ-
ence of reader experience. Our data cannot be directly
extrapolated to malignant tissue, particularly those
with less conspicuous margins (in which case, we
would hypothesize that the variability in our measure-
ments would increase), because uterine fibroids are
not malignant. However, our data do provide some
insight into the variability that might still arise from
multiple readers performing the same measurements
on the same cases, postprocessed using the same
workstation.
Table 3
Fraction of Variance Explained by Differences in Uterine Fibroids,
Readers, and Random Error Using Random-Effect Analyses of






iAUC (P < 0.0001, R2 ¼ 0.75)
Uterine fibroid 82.9% 73.0% 68.5%
Reader 3.0% 1.5% 10.3%
Error 14.1% 25.6% 21.2%
Ktrans (P < 0.0001, R2 ¼ 0.75)
Uterine fibroid 89.4% 74.1% 67.7%
Reader 1.6% 1.5% 14.1%
Error 9.0% 24.4% 18.2%
kep (P < 0.0001, R
2 ¼ 0.60)
Uterine fibroid 98.2% 46.9% 55.9%
Reader 0.1% 0.5% 0.4%
Error 1.7% 52.6% 43.7%
ve (P < 0.0001, R
2 ¼ 0.69)
Uterine fibroid 88.7% 72.3% 64.8%
Reader 0.6% <0.1% 4.2%
Error 10.7% 27.7% 31.0%
P values and adjusted R2 values refer to model significance. The
readers and uterine fibroids were considered random effects and
the ROI method was considered a fixed effect.
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There are some limitations of our study. Our DCE
datasets were derived using a TWIST sequence, which
is different from the traditional 2D or 3D T1-weighted
spoiled gradient echo sequences used in most DCE
studies. We use TWIST to optimize the frame rate, but
the unique method of k-space undersampling TWIST
uses may limit our ability to generalize the results of
this study to other DCE imaging protocols. Our meas-
ured variability could be more or less with a tradi-
tional protocol. Additionally, each of the five readers
in this study was either a senior radiology resident or
a board-certified abdominal imaging fellow who had
received prestudy training on DCE analysis. It is pos-
sible that readers with more experience using the
postprocessing tool or interpreting pelvic MR in gen-
eral would have improved intra-rater reproducibility.
However, each reader was trained and then evaluated
by an experienced MR reader before study initiation
to confirm training adequacy. Each reader was, there-
fore, skilled in the use of the postprocessing tool and
competent with respect to all ROI placement method-
ologies before beginning the study.
In conclusion, under relatively constant conditions
the mean intra-rater within-subject CVs for Ktrans,
kep, ve, and iAUC using the same ROI selection
method and postprocessing algorithm on identical
TWIST DCE-MRI datasets were 4.6–7.6%, suggesting
that changes of up to 9–15% may be attributable to
measurement error. A large ROI encompassing at
least three-quarters of the lesion had the greatest
inter-rater reproducibility, while the user-defined ROI
had the least inter-rater reproducibility. Our findings
represent measurements performed in a uterine
fibroid model and may not be a true reflection of
general oncologic practice. Further studies would be
needed to validate our results in that context.
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